Lyra Therapeutics (LYRA) Stock Price, News & Analysis

Company Overview

Lyra Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing targeted drug delivery therapies for diseases of the ear, nose and throat (ENT). Leveraging its proprietary Therapeutic Drug Delivery (TDD) platform, the company designs bioresorbable, steroid-eluting implants that provide sustained, localized release of medication directly to affected tissue. This approach aims to improve patient outcomes by reducing the need for repeated administration and minimizing systemic side effects.

The company’s lead product candidate, LYR-210, is an implantable matrix that delivers the corticosteroid mometasone furoate over several months to treat chronic rhinosinusitis (CRS). LYR-210 is currently advancing through pivotal Phase 3 clinical trials, following positive Phase 2 data demonstrating significant improvements in symptom control and quality of life measures. In addition, Lyra is developing LYR-220 for chronic obstructive pulmonary disease (COPD) and exploring other respiratory indications, all based on its sustained-release implant technology.

Founded in 2015 and headquartered in Lynnfield, Massachusetts, Lyra Therapeutics operates research and development facilities in the United States. The company is led by President and Chief Executive Officer Bryan J. Bork, supported by a management team with extensive expertise in drug delivery, drug development and regulatory strategy. As Lyra advances its pipeline through clinical development, it seeks to establish partnerships for commercial manufacturing and expand its platform into additional ENT and respiratory disease areas.

Key Stats

• Today's Range: $0.59 to $0.78
• 50-Day Range: $0.40 to $1.46
• 52-Week Range: $0.31 to $37.50
• Volume: 33,471 shs
• Average Volume: 75,535 shs
• Market Capitalization: $1.30 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Reduce

LYRA Stock Analysis - Frequently Asked Questions

How have LYRA shares performed this year?

Lyra Therapeutics' stock was trading at $3.08 at the beginning of 2026. Since then, LYRA shares have decreased by 76.3% and is now trading at $0.73.

How were Lyra Therapeutics' earnings last quarter?

Lyra Therapeutics, Inc. (NASDAQ:LYRA) issued its quarterly earnings results on Wednesday, November, 12th. The company reported ($3.38) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($5.98) by $2.60. The company had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.21 million. Lyra Therapeutics had a negative trailing twelve-month return on equity of 1,010.91% and a negative net margin of 5,491.17%.

When did Lyra Therapeutics' stock split?

Shares of Lyra Therapeutics reverse split before market open on Wednesday, May 28th 2025.A 1-50 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 27th 2025. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

When did Lyra Therapeutics IPO?

Lyra Therapeutics (LYRA) raised $52 million in an initial public offering on Friday, May 1st 2020. The company issued 3,500,000 shares at $14.00-$16.00 per share. BofA Securities, Jefferies and William Blair acted as the underwriters for the IPO and BTIG was co-manager.

How do I buy shares of Lyra Therapeutics?

Shares of LYRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Lyra Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Lyra Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), CrowdStrike (CRWD), ServiceNow (NOW) and Adobe (ADBE).

Company Calendar

• Last Earnings: 11/12/2025
• Today: 5/06/2026
• Next Earnings (Estimated): 5/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:LYRA
• CIK: 1327273
• Web: www.lyratherapeutics.com
• Phone: 617-393-4600
• Fax: N/A
• Employees: 50
• Year Founded: 2005

Profitability

• EPS (Trailing Twelve Months): ($19.15)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$93.43 million
• Net Margins: -5,491.17%
• Pretax Margin: -5,488.67%
• Return on Equity: -1,010.91%
• Return on Assets: -58.92%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.43
• Quick Ratio: 2.43

Sales & Book Value

• Annual Sales: $600 thousand
• Price / Sales: 2.16
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.86 per share
• Price / Book: 0.08

Miscellaneous

• Outstanding Shares: 1,775,000
• Free Float: 1,717,000
• Market Cap: $1.30 million
• Optionable: No Data
• Beta: 0.68